Veliparib
- Generic Name
- Veliparib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C13H16N4O
- CAS Number
- 912444-00-9
- Unique Ingredient Identifier
- 01O4K0631N
- Indication
与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。
- Associated Conditions
- -
- Associated Therapies
- -
A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 160
- Registration Number
- NCT01560104
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- First Posted Date
- 2012-02-29
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT01540565
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸The Hospital of Central Connecticut, New Britain, Connecticut, United States
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
- Conditions
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT01514201
- Locations
- 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 294
- Registration Number
- NCT01506609
- Locations
- 🇨🇦
Sunnybrook Health Sciences Ctr /ID# 77373, Toronto, Ontario, Canada
🇺🇸The Angeles Clinic and Researc /ID# 60743, Los Angeles, California, United States
🇺🇸University of Pennsylvania /ID# 60753, Philadelphia, Pennsylvania, United States
Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT01477489
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT01472783
- Locations
- 🇩🇰
Department of Oncology, Vejle Hospital, Vejle, Denmark
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT01459380
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 121
- Registration Number
- NCT01434316
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT01386385
- Locations
- 🇺🇸
Queen's Medical Center, Honolulu, Hawaii, United States
🇺🇸Straub Clinic and Hospital, Honolulu, Hawaii, United States
🇺🇸Crossroads Cancer Center, Effingham, Illinois, United States
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT01366144
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.